Compare Automatic Data Processing Inc (ADP) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Sanofi SA — how do they compare? Automatic Data Processing Inc trades at $268.05 (market cap $107.69B), while Sanofi SA trades at $43.49 (market cap $104.30B). The key difference: Automatic Data Processing Inc and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ADP | SNY | |
|---|---|---|
Market Cap | $107.69B | $104.30B |
Sector | Industrials | Health |
52-Week High | $309.03 | $52.34 |
52-Week Low | $188.79 | $41.33 |
Enterprise Value | $108.73B | $124.19B |
Dividend Yield | 2.51% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $273.68, up 0.87% today, near its consensus price target of $280.50. The stock shows bullish technical signals with strong moving averages and support at $270. Recent quarterly earnings consistently beat estimates, with Q2 2026 EPS of $2.64 surpassing the $2.59 forecast. Revenue growth is steady, reaching $20.56 billion in 2025, with a net income margin of 20.11% and robust ROE of 72.24%.
Outlook remains positive given earnings momentum and dividend stability, but high valuation multiples (P/E 24.78, P/S 4.98) pose risks if growth slows. Analyst sentiment is mixed with 63.89% hold ratings, reflecting caution amid elevated prices. Key risks include labor market sensitivity and competitive pressures in payroll processing.
SNY trades at $43.48, showing minimal daily change. The technical outlook is neutral with mixed signals, while the stock hovers near its pivot point of $44. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 sales guidance. Revenue for 2025 was $46.72B with a net income margin of 16.72%, though a decline is projected for 2026. Recent news highlights regulatory approvals for new drugs and strategic shifts under a new CEO.
The investment outlook is cautiously optimistic, supported by earnings beats and positive guidance, but tempered by a projected profit margin contraction in 2026 and a neutral analyst consensus. Key opportunities include growth from Dupixent and new drug approvals, while risks involve pipeline setbacks, competitive pressures, and potential legal challenges. The stock presents a value case with a reasonable P/E of 23.27, but requires monitoring of execution under new leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
